Display options
Share it on

Oncol Rep. 1997 Jan-Feb;4(1):93-6.

Study of angiotensin II-induced hypertensive chemotherapy for ovarian cancer in rats.

Oncology reports

H Nishimura, Y Kiyozuka, K Imamura, H Higashijima, M Yakushiji

Affiliations

  1. KANSAI MED UNIV,DEPT PATHOL,KURUME,FUKUOKA,JAPAN. KURUME UNIV,SCH MED,DEPT OBSTET & GYNECOL,KURUME,FUKUOKA 830,JAPAN.

PMID: 21590018

Abstract

We investigated the usefulness of angiotensin II (AT II)-induced hypertensive chemotherapy for adenocarcinoma of the ovary, which was induced with dimethylbenzantracene (DMBA) in rats. Ovaries with DMBA-induced cancer had poor blood flow, while normal ovaries had abundant brood flow when blood pressure was normal. The brood flow of the normal ovaries was suppressed by AT II-induced hypertension, while the blood flow in ovarian cancer was more than doubled. Tissue levels of the anticancer drug cisplatin (CDDP) were almost the same in the normal ovary in the presence or absence of induced hypertension. However, the CDDP level in ovarian cancer tissue was significantly higher with AT II-induced hypertension than with normotension. Comparison of the ratio of the enlarged tumor to the primary tumor and the histopathologic antitumor effects, showed that AT II-induced hypertension treatment with CDDP was highly effective. Angiotensin II-induced hypertensive chemotherapy for adenocarcinoma of the ovary in rat was highly effective in comparison with normotension.

Publication Types